Grifols, S.A. (NASDAQ:GRFS) Shares Acquired by Chesapeake Capital Corp IL

Chesapeake Capital Corp IL lifted its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 49.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,638 shares of the biotechnology company’s stock after purchasing an additional 8,138 shares during the quarter. Chesapeake Capital Corp IL’s holdings in Grifols were worth $183,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Atria Investments Inc acquired a new stake in Grifols in the 3rd quarter valued at $344,000. Oppenheimer Asset Management Inc. grew its stake in Grifols by 5.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 58,677 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 2,790 shares during the period. Natixis Advisors LLC grew its stake in Grifols by 40.0% in the 3rd quarter. Natixis Advisors LLC now owns 215,667 shares of the biotechnology company’s stock valued at $1,915,000 after acquiring an additional 61,614 shares during the period. Anthracite Investment Company Inc. acquired a new stake in Grifols in the 3rd quarter valued at $5,457,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Grifols by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 31,543 shares of the biotechnology company’s stock valued at $280,000 after acquiring an additional 2,301 shares during the period.

Grifols Stock Performance

Shares of GRFS opened at $8.10 on Wednesday. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The firm’s fifty day moving average is $7.51 and its two-hundred day moving average is $8.11. The stock has a market cap of $5.57 billion, a PE ratio of 6.92 and a beta of 0.35.

Analyst Ratings Changes

Separately, Morgan Stanley started coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.